Dimethyl fumarate-induced changes in the MS lymphocyte repertoire: No need for subset monitoring

Slow-release dimethyl fumarate (DMF) is the most widely prescribed oral disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS). Class I evidence indicates that DMF reduces relapse rates, MRI disease activity, and, to a lesser extent, disability progression in RRMS.^1,2 Apart from flushing, gastrointestinal symptoms, and (infrequently severe) lymphopenia, the drug is well-tolerated. Real-world comparison of oral DMTs showed slightly variable results, but suggest that DMF is roughly similar in reducing relapses compared to other oral DMTs, that is, fingolimod and teriflunomide,³ especially when used in naive patients.⁴

from Neurology recent issues http://bit.ly/2U4njsk